View Older Stories View More Recent Stories
-
Superior Drilling Products, Inc. Announces Pricing of Follow-on Equity Offering
-
Delcath Systems (DCTH) to Offer Common Stock and Warrants
-
Delcath Announces Proposed Public Offering of Common Stock and Warrants
-
Notable Analyst Rating Changes 9/29: (OZM) (EBAY) (EMES) Upgraded; (AAPL) (FIT) (MANT) Downgraded
-
Pre-Open Stock Movers 09/29: (AEGR) (ARWR) (EBAY) Higher; (ITCI) (ADHD) (FIT) Lower (more...)
-
Actinium Pharma (ATNM) Prices 8M Common Stock Offering at $1.25/Share
-
Actinium Announces Pricing of Public Offering of Common Stock
-
Roth Capital Starts CEVA Inc. (CEVA) at Buy
-
After-Hours Stock Movers 09/28: (AEGR) (PIR) (GSAT) Higher; (ITCI) (ATNM) (PRGS) Lower (more...)
-
Roth Capital Starts Ambarella (AMBA) at Buy
-
Roth Capital Starts Magnachip Semiconductor (MX) at Buy
-
Roth Capital Starts Silicon Motion Technology (SIMO) at Buy
-
Roth Capital Starts Silicon Labs (SLAB) at Buy
-
Roth Capital Starts Integrated Device Technology (IDTI) at Buy
-
Roth Capital Starts Himax Technologies (HIMX) at Buy
-
Roth Capital Downgrades Galectin Therapeutics (GALT) to Sell
-
Roth Capital Reaffirms Actinium Pharma (ATNM) at 'Buy'; Says Starting Actimab-A Phase 2 is 'Important Step'
-
Roth Capital Affirms Pieris Pharma (PIRS) at 'Buy' Following Positive PRS-343 Data
-
Roth Capital Trims PT on Ligand Pharma (LGND) to $150 Amid New Kyprolis Data (AMGN)
-
Roth Capital Keeps Ballard Power (BLDP) at 'Buy' Amid New Audi Orders
-
Streetinsider.com's Hot Lunchtime Reads 9/26: (REGN) (ONTX) (LITE) (SFL)
-
Roth Capital Reaffirms Regeneron (REGN) at 'Buy'; Dupilumab BLA in AD Key Next Step in Development
-
Roth Capital Downgrades Digital Turbine (APPS) to Neutral
-
Roth Capital Keeps BioLineRx (BLRX) at 'Buy' Amid New in-Licensing Agreement
-
Roth Capital Starts Mindbody (MB) at Buy
-
Roth Trims PT on Enphase Energy (ENPH) to $1.50 Amid Restructuring, Equity Offering
-
Roka Bioscience, Inc. Completes Private Placement of Preferred Stock and Warrants
-
Roth Capital Starts Fate Therapeutics (FATE) at Buy
-
Roth Capital Assumes bluebird bio (BLUE) at Buy
-
Azure Power Global Limited Announces Launch of its Initial Public Offering
-
Streetinsider.com's Hot Lunchtime Reads 9/21: (LL) (RHT) (CUR) (TSLA)
-
Roth Capital Affirms Neuralstem (CUR) at 'Buy' Amid NSI-189 Enrollment Milestone
-
Capricor Therapeutics Announces Closing of Public Offerings Raising Approximately $10.0 Million in Net Proceeds
-
Klay Thompson, Kelly Slater, Rob Machado and 400 Individuals Supported Ryan Sheckler's Gala and 9th Annual Golf Tournament Sponsored by Oakley
-
Roth Capital Reaffirms Palatin Technologies (PTN) at 'Buy'; Focus Now on BMT Phase III Data
-
Roth Capital Reiterates Regeneron (REGN) at 'Buy' Following New Teva Pharma Ffasinumab Partnership
-
Pre-Open Stock Movers 09/16: (DEPO) (INTC) (GPRO) Higher; (NVAX) (DB) (ORCL) Lower (more...)
-
Capricor Therapeutics (CAPR) Prices 3M Common Stock Offering for Proceeds of ~$8.7M
-
Capricor Therapeutics Announces Pricing of Offerings of Common Stock
-
Roth Capital Starts Recro Pharma (REPH) at Buy
-
Roth Capital Affirms S&W Seed (SANW) at 'Buy' Following Q4 Results; Says Margin Improvement Remains Key
-
Callidus Software, Inc. (CALD) Prices 5.1M Common Stock Follow-on at $18.25/Share
-
CallidusCloud Announces Pricing of Follow-On Offering
-
After-Hours Stock Movers 09/15: (SCOR) (CAR) (P) Higher; (NVAX) (DB) (ORCL) Lower (more...)
-
Capricor Therapeutics (CAPR) Announces Common Stock Offering
-
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
-
Notable Analyst Rating Changes 9/15: (GPN) (AKRX) (EXTR) Upgraded; (VFC) (FGP) (ATRA) Downgraded
-
Pre-Open Stock Movers 09/15: (AERI) (ACRX) (NTWK) Higher; (SQNS) (PAH) (SRPT) Lower (more...)
-
Roth Capital Downgrades Apigee (APIC) to Neutral
-
Roth Capital Starts Sophiris Bio (SPHS) at Buy, $8 PT

